Novo Nordisk cuts Innate Pharma stake below 5% voting rights threshold

• Novo Nordisk cut its stake in Innate Pharma below 5% of voting rights on March 31, 2026.
• Holding stood at 4,718,727 shares, equal to 5% of capital, 5% of voting rights.
• Stake fell below 5% of share capital on April 1, 2026, to 4,636,451 shares.
• Position represented 5% of capital, 4.9% of voting rights.
• Disposals were executed via market sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on April 13, 2026, and is solely responsible for the information contained therein.